Chargement en cours...

Investigational FMS-Like Tyrosine Kinase 3 (FLT3) Inhibitors in Treatment of Acute Myeloid Leukemia (AML)

INTRODUCTION: Outcomes for the majority of patients with Acute Myeloid Leukemia (AML) remain poor. Over the past decade, significant progress has been made in the understanding of the cytogenetic and molecular determinants of AML pathogenesis. One such advance is the identification of recurring muta...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Pemmaraju, Naveen, Kantarjian, Hagop, Andreeff, Michael, Cortes, Jorge, Ravandi, Farhad
Format: Artigo
Langue:Inglês
Publié: 2014
Sujets:
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4109297/
https://ncbi.nlm.nih.gov/pubmed/24749672
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1517/13543784.2014.911839
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!